Rensselaer Polytechnic Institute (RPI)

In Cell Studies, Seaweed Extract Outperforms Remdesivir in Blocking COVID-19 Virus

Heparin, a common anitcoagulent, could also form basis of a viral trap for SARS-CoV-2

Newswise — TROY, N.Y. — In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.

Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.

The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.

Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A. To hear the researchers discuss their findings, watch this video.

“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.” 

The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.

The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.

RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.

A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.

 “What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”

Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.” 

In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.

“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.” 

Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides. 

“This exciting research by Professors Dordick and Linhardt is among several ongoing research efforts at CBIS, as well as elsewhere at Rensselaer, to tackle the challenges of the COVID-19 pandemic through novel therapeutic approaches and the repurposing of existing drugs,” said CBIS Director Deepak Vashishth.

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro” was published in Cell Discovery with the support of the National Research Foundation of Korea. At Rensselaer, Dordick and Linhardt were joined in the research by Paul S. Kwon, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, and Keith Fraser, and by researchers at the Korea Research Institute of Bioscience and Biotechnology in Cheongju, Republic of Korea, and Zhejiang University of Technology in Hangzhou, China.

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, 32 research centers, more than 145 academic programs, and a dynamic community made up of more than 7,900 students and over 100,000 living alumni. Rensselaer faculty and alumni include more than 145 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit www.rpi.edu.

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6117
Newswise:Video Embedded spreading-doses-of-hope-as-covid-19-cases-rise
VIDEO
Released: 4-Aug-2021 10:35 AM EDT
Spreading ‘Doses of Hope’ as COVID-19 Cases Rise
Cedars-Sinai

In an emotional new series of videos, Black medical professionals plead for viewers to get a COVID-19 vaccine.

Newswise:Video Embedded american-college-of-surgeons-urges-surgeons-to-talk-it-up-with-patients-about-covid-19-vaccination
VIDEO
Released: 4-Aug-2021 10:00 AM EDT
American College of Surgeons Urges Surgeons to “Talk It Up” with Patients About COVID-19 Vaccination
American College of Surgeons (ACS)

ACS is launching a “Talk It Up” campaign to help surgeons address patient concerns and help them understand the importance of getting vaccinated against COVID-19.

28-Jul-2021 11:15 AM EDT
LEDs Light the Way to Coronavirus Disinfection
American Institute of Physics (AIP)

LEDs are commonly used for sterilization, and in the continued effort to combat the coronavirus pandemic, LEDs can also help inactivate SARS-CoV-2. A team in Pakistan designed far-ultraviolet LEDs at a targeted wavelength of 222 nanometers, chosen both for its ability to inactivate the virus and for being safe on human skin. They based their design on the material aluminum gallium nitride, part of a set of materials called III-nitrides which are efficient, inexpensive, and environmentally friendly.

Newswise: Text-Message ‘Nudges’ Can Encourage Holdouts to Get COVID Vaccination, Study Finds
Released: 4-Aug-2021 8:50 AM EDT
Text-Message ‘Nudges’ Can Encourage Holdouts to Get COVID Vaccination, Study Finds
University of California, Los Angeles (UCLA), Health Sciences

New UCLA-led research indicates that simple text messages emphasizing the easy availability of COVID-19 vaccines successfully boosted the number of people who got the shot.

Newswise: The Future of Masking Post-Vaccination
Released: 4-Aug-2021 8:45 AM EDT
The Future of Masking Post-Vaccination
Rush University Medical Center

The COVID-19 vaccine is your best defense against the virus, but when and where should you continue to wear a mask? Rush infectious disease expert Michael Lin, MD, answers questions about wearing a mask post-vaccination.

Newswise: COVID-19 Infection Rate Low Among Rural Health Care Workers
Released: 4-Aug-2021 8:40 AM EDT
COVID-19 Infection Rate Low Among Rural Health Care Workers
South Dakota State University

Antibody testing of health care workers in three rural counties in eastern South Dakota and western Minnesota showed 15% had antibodies to the novel coronavirus.

Newswise: New Study Details Enzyme That Allows Coronavirus to Resist Antiviral Medications
Released: 3-Aug-2021 12:20 PM EDT
New Study Details Enzyme That Allows Coronavirus to Resist Antiviral Medications
Iowa State University

A new Iowa State University study details the structure of a critical enzyme present in SARS-CoV-2, the coronavirus that causes COVID-19. This enzyme removes nucleoside antiviral medications from the virus’s RNA, rendering many treatments ineffective. Scientists could use data uncovered in the new study to find ways to inhibit the enzyme, possibly leading to more effective treatments.

Released: 2-Aug-2021 6:05 PM EDT
Rethinking Remdesivir
University of California San Diego Health

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.

Newswise: Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Released: 2-Aug-2021 4:25 PM EDT
Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Hackensack Meridian Health

New COVID-19 40-day mortality risk model, published in The Public Library of Science ONE, has potential for use in patient treatment planning, comparisons of therapeutic strategies, and public-health preparations.


Showing results

110 of 6117

close
1.79006